Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.185
-0.145 (-4.35%)
At close: Nov 13, 2026, 4:00 PM EST
3.100
-0.085 (-2.67%)
Pre-market: Nov 16, 2026, 8:55 AM EST
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenue of $18.55M in the quarter ending September 30, 2026, with 258.49% growth. This brings the company's total for the last twelve months to $68.23M, up 56.18% year-over-year. In the year 2025, Recursion Pharmaceuticals had annual revenue of $74.68M with 26.92% growth. That makes Recursion Pharmaceuticals the 25,653rd largest company in the world by revenue and 3,553rd in the United States.
Revenue (ttm)
$68.23M
Revenue Growth
+56.18%
P/S Ratio
29.10
Revenue / Employee
$113,720
Employees
600
Market Cap
1.99B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Recursion Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 74.68M | 15.84M | 26.92% |
| Dec 31, 2024 | 58.84M | 14.26M | 32.00% |
| Dec 31, 2023 | 44.58M | 4.73M | 11.88% |
| Dec 31, 2022 | 39.84M | 29.67M | 291.46% |
| Dec 31, 2021 | 10.18M | 6.22M | 156.89% |
| Dec 31, 2020 | 3.96M | 1.64M | 70.85% |
| Dec 31, 2019 | 2.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.67B |
| Harmony Biosciences Holdings | 989.36M |
| Maravai LifeSciences Holdings | 213.00M |
| Agios Pharmaceuticals | 140.84M |
| Septerna | 96.27M |
| Maze Therapeutics | 20.00M |
RXRX News
- 1 hour ago - Recursion Pharmaceuticals price target lowered to $7 from $10 at JPMorgan - TheFly
- 5 days ago - Recursion to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 13 days ago - Recursion Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 13 days ago - Recursion Pharmaceuticals Earnings release: Q3 2026 - Filings
- 13 days ago - Recursion Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 13 days ago - Recursion Pharmaceuticals Slides: Q3 2026 - Filings
- 13 days ago - Recursion Pharmaceuticals reports Q3 EPS (22c), consensus (23c) - TheFly
- 13 days ago - Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair - GlobeNewsWire